PharmaCyte Biotech, Inc.

PMCBNASDAQHealthcare● Active

$0.70

+$0.00(+0.00%)

Market Cap$4757046

P/E Ratio—

52W High$1.51

52W Low$0.63

Avg Volume199K

Open$0.71

Beta0.52

Net Income Financials Revenue

PharmaCyte Biotech, Inc. (PMCB) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

PMCB · net income · updated Jun 9, 2026

Core profitability metrics

PMCB · net income · margin · TTM · CAGR

Net income was $30.7M for FY2025 (fiscal year ending 2025-04-30), up 9085.0% year-over-year. Net profit margin was —. Based on available data, PharmaCyte Biotech, Inc. has been profitable since at least 2024.

FY2025 Net Income$30.7M▲ +9085.0% YoY

Trailing 12M (TTM)−$3.3Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+9085.0%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2024

▸ FMP /income-statement · Annual · PMCB net income history · PMCB profit margin

Annual net income data

PMCB · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$30.7M▲ +9085.0%—$0

FY2024★ First Profit$333,763▲ +107.7%—$0

FY2023Loss−$4.3M▼ 1.8%—$0

FY2022Loss−$4.2M▼ 19.3%—$0

FY2021Loss−$3.6M▲ +7.1%—$0

Net income vs peers (Healthcare)

PMCB vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

PharmaCyte Biotech, Inc.YOU

PMCB

$30.7M+9085.0%—

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

PharmaCyte Biotech, Inc. (PMCB) reported net income of $30.7M for FY2025 (fiscal year ending 2025-04-30), up 9085.0% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Based on available data, PharmaCyte Biotech, Inc. has been profitable since at least 2024. Net income reached a peak of $30.7M in FY2025. Data available for 15 fiscal years.

PharmaCyte Biotech, Inc.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "PharmaCyte Biotech, Inc. net worth" — the company's market capitalization is a separate figure from PMCB net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

PMCB net income · 5 questions

PharmaCyte Biotech, Inc. is profitable. The company reported net income of $30.7M for FY2025, a net profit margin of —. Net income was up 9085.0% year-over-year. Based on available data, PharmaCyte Biotech, Inc. has been profitable since at least 2024.

is PMCB profitabledoes PMCB make a profitPMCB profitabilityPMCB profitable company

▸ Source: FMP /income-statement · GAAP · PharmaCyte Biotech, Inc. · PharmaCyte Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026